Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma

Cancer Imaging

Volumn 12, Issue 3, 2012, Pages 464-474

  Wang, Hsin Yi ^a,b   Ding, Hueisch Jy ^c   Chen, Jin Hua ^d   Chao, Chih Hao ^e   Lu, Yu Yu ^a   Lin, Wan Yu ^a,f   Kao, Chia Hung ^f,g  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHANG BING SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

FDG; Meta analysis; PET; PET CT; Renal cell carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXTERNAL VALIDITY; HUMAN; INTERNAL VALIDITY; KIDNEY CARCINOMA; MEDLINE; META ANALYSIS; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84870562414     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2012.0042     Document Type: Review

References (37)

1. Frank IN, Graham SD, Nabors WL. Urologic and male genital cancers. In: Holleb AI, Fink DJ, Murphy GP, editors. Clinical oncology. Atlanta, GA: American Cancer Society; 1991, p. 283-287.
2. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002; 32: 35-46. PMid:11839068.
3. Scott AM. Current status of positron emission tomography in oncology. Australas Radiol 2002; 46: 154-162. doi:10.1046/j.1440-1673.2001.01025.x. PMid:12060153.
4. Martinez de Llano SR, Delgado-Bolton RC, Jimenez-Vicioso A, et al. [Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma]. Rev Esp Med Nucl 2007; 26: 19-29 (in Spanish). doi:10.1157/13097378. PMid:17286945.
5. Tavani A, La Vecchia C. Epidemiology of renal-cell carcinoma. J Nephrol 1997; 10: 93-106. PMid:9238616.
6. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet 1997; 350: 185-186. doi:10.1016/S0140-6736(05)62352-5. PMid:9250191.
7. Cochrane Methods Working Group on Systematic Review of Screening and Diagnostic Tests: Recommended Methods. June 6, 1996; Available from: http://www.cochrane.org/cochrane/sadtdoc1.htm.
8. Brennan P, Silman A. Statistical methods for assessing observer variability in clinical measures. BMJ 1992; 304: 1491-1494. doi:10.1136/bmj.304. 6840.1491. PMid:1611375.
9. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003; 21: 19-22. doi:10.1002/ssu.10017. PMid:12923912.
10. Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. Stat Med 1993; 12: 2273-2284. doi:10.1002/sim.4780122405. PMid:7907813.
11. Deeks JJ. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-162. doi:10.1136/bmj.323.7305.157. PMid:11463691.
12. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825-830. doi:10.1016/S0022-5347(05) 65845-4. PMid:11490227.
13. 18F-fluoro-2- deoxyglucose positron emission tomography - a preliminary report. Urol Int 2003; 71: 306-309. doi:10.1159/000072683. PMid:14512653.
14. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9: 15-18. doi:10.1046/j.1442-2042.2002.00416.x. PMid:11972644.
15. Safaei A, Figlin R, Hoh CK, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for restaging of renal cell cancer. Clin Nephrol 2002; 57: 56-62. PMid:11837802.
16. 18F-2- deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol 2002; 128: 503-506. PMid:12242515.
17. Aide N, Cappele O, Bottet P, et al. Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol 2003; 30: 1236-1245. doi:10.1007/s00259-003-1211-4. (Pubitemid 37205377)
18. Jadvar H, Kherbache HM, Pinski JK, et al. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 2003; 60: 395-400. PMid:14690256.
19. Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21: 3995-4000. doi:10.1200/JCO.2003.04.073. PMid: 14581422.
20. Kang DE, White RL, Jr. Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004; 171: 1806-1809. doi:10.1097/01.ju.0000120241.50061.e4. PMid:15076281.
21. Park JW, Jo MK, Lee HM. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009; 103: 615-619. doi:10.1111/j.1464-410X.2008.08150.x. PMid:19007371.
22. Nakatani K, Nakamoto Y, Saga T, et al. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol 2011; 79: 29-35. doi:10.1016/j.ejrad.2009.11.019. PMid:20015602.
23. Kumar R, Shandal V, Shamim SA, et al. Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun 2010; 31: 844-850. PMid:20661166.
24. Rodriguez Martinez de Llano S, Jimenez-Vicioso A, Mahmood S, et al. Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma. Rev Esp Med Nucl 2010; 29: 12-19. doi:10.1016/j.remn.2009.11.008. PMid:20022140.
25. Ozulker T, Ozulker F, Ozbek E, et al. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun 2011; 32: 265-272. doi:10.1097/MNM.0b013e3283442e3b. PMid:21301376.
26. Bechtold RE, Zagoria RJ. Imaging approach to staging of renal cell carcinoma. Urol Clin North Am 1997; 24: 507-522. doi:10.1016/S0094-0143(05) 70399-2. PMid:9275976.
27. Levine E. Renal cell carcinoma: clinical aspects, imaging diagnosis, and staging. Semin Roentgenol 1995; 30: 128-148. doi:10.1016/S0037-198X(05)80030-6. PMid:7610402.
28. Zagoria RJ, Bechtold RE, Dyer RB. Staging of renal adenocarcinoma: role of various imaging procedures. AJR Am J Roentgenol 1995; 164: 363-370. PMid:7839970.
29. Hilton S. Imaging of renal cell carcinoma. Semin Oncol 2000; 27: 150-159. PMid:10768594.
30. Wahl RL, Harney J, Hutchins G, et al. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol 1991; 146: 1470-1474. PMid:1942320.
31. Bachor R, Kotzerke J, Gottfried HW, et al. [Positron emission tomography in diagnosis of renal cell carcinoma]. Urologe A 1996; 35: 146-150 (in German). PMid:8650849.
32. Kumar R, Chauhan A, Lakhani P, et al. 2-Deoxy-2-[F-18] fluoro-D-glucose-positron emission tomography in characterization of solid renal masses. Mol Imaging Biol 2005; 7: 431-439. doi:10.1007/s11307-005-0026-z. PMid:16307216.
33. Kamel EM, Jichlinski P, Prior JO, et al. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med 2006; 47: 1803-1807. PMid:17079813.
34. Southworth R, Parry CR, Parkes HG, et al. Tissue-specific differences in 2-fluoro-2-deoxyglucose metabolism beyond FDG-6-P: a 19F NMR spectroscopy study in the rat. NMR Biomed 2003; 16: 494-502. doi:10.1002/nbm.856. PMid:14696007.
35. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol 1996; 270 (4 Pt 1): G541-553. PMid:8928783.
36. Montravers F, Grahek D, Kerrou K, et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41: 78-84. PMid:10647608.
37. Sacco E, Pinto F, Totaro A, et al. Imaging of renal cell carcinoma: state of the art and recent advances. Urol Int 2011; 86: 125-139. doi:10.1159/000322724. PMid:21150177.